(S)-N-(2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide | 1129693-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (S)-N-(2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide
• 英文别名: N-[(6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl]-2-[4-(trifluoromethoxy)phenoxy]acetamide
• CAS: 1129693-22-6
• 化学式: C₁₅H₁₃F₃N₄O₆
• 分子量: 402.287
• InChiKey: WRRSLLXFFKADJH-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-(三氟甲氧基)苯氧基乙酰氯 、 (S)-2-硝基-6,7-二氢-5H-咪唑并[2,1-B][1,3]噁嗪-6-胺 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以0.27 g的产率得到(S)-N-(2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-2-(4-(trifluoromethoxy)phenoxy)acetamide
  参考文献：
  名称：

  抗结核硝基咪唑的构效关系。2. 有氧活动的决定因素和数量结构-活动关系

  摘要：

  ( S )-2-硝基-6-取代的6,7-二氢-5 H-咪唑并[2,1- b ][1,3]恶嗪类化合物由于其优异的性能而被广泛探索作为新型抗结核药物的潜在用途。结核分枝杆菌需氧全细胞的杀菌特性. 有氧活性需要咪唑环 2-位上的氧原子。在这里，我们表明用氮或硫取代这种氧会产生等效的类似物。酰化氨基系列、氧化硫醚或用碳取代醚氧显着降低了化合物的效力。用氮替换 6 位的苄氧稍微提高了效力，并促进了对更易溶的 6-氨基系列中 SAR 的探索。通过在 6-( S ) 位置和末端疏水性芳族取代基之间扩展接头区域，实现了效力的显着改进。一个简单的四特征 QSAR 模型被推导出来合理化这一系列双环硝基咪唑的 MIC 结果。

  DOI：

  10.1021/jm801374t

文献信息

• Structure–Activity Relationships for Amide-, Carbamate-, And Urea-Linked Analogues of the Tuberculosis Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)
  作者：Adrian Blaser、Brian D. Palmer、Hamish S. Sutherland、Iveta Kmentova、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、Andrew M. Thompson、William A. Denny

  DOI：10.1021/jm2012276

  日期：2012.1.12

  Analogues of clinical tuberculosis drug (6S)-2-nitro-6-[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824), in which the OCH2 linkage was replaced with amide, carbamate, and urea functionality, were investigated as an alternative approach to address oxidative metabolism, reduce lipophilicity, and improve aqueous solubility. Several soluble monoaryl examples displayed moderately improved (similar to 2- to 4-fold) potencies against replicating Mycobacterium tuberculosis but were generally inferior inhibitors under anaerobic (nonreplicating) conditions. More lipophilic biaryl derivatives mostly displayed similar or reduced potencies to these in contrast to the parent biaryl series. The leading biaryl carbamate demonstrated exceptional metabolic stability and a 5-fold better efficacy than the parent drug in a mouse model of acute M. tuberculosis infection but was poorly soluble. Bioisosteric replacement of this biaryl moiety by arylpiperazine resulted in a soluble, orally bioavailable carbamate analogue providing identical activity in the acute model, comparable efficacy to OPC-67683 in a chronic infection model, favorable pharmacokinetic profiles across several species, and enhanced safety.